# OnCo record nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "nsclc" ;
  schema:name "Non-small-cell lung cancer"@en ;
  schema:alternateName "LUAD"@en, "LUSC"@en, "LSCC"@en, "TCGA-LUAD"@en, "TCGA-LUSC"@en, "lung adenocarcinoma (TCGA LUAD cohort)"@en, "lung squamous cell carcinoma (TCGA LUSC and CPTAC LSCC cohorts)"@en ;
  schema:description "Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."@en ;
  schema:url <https://onco.cc/cancers/nsclc/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3658562> ;
  schema:citation <https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer> ;
  onco:tag "lung", "spike" ;
  onco:related <https://onco.cc/cancers/sclc/>, <https://onco.cc/roadmaps/kras-roadmap/>, <https://onco.cc/roadmaps/adc-generations/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/pairings/targeted-before-io-nsclc/>, <https://onco.cc/pairings/amivantamab-plus-lazertinib/>, <https://onco.cc/pairings/tki-then-adc-lung/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/omega3-epa-cachexia/>, <https://onco.cc/technologies/shark-cartilage/>, <https://onco.cc/technologies/hydrazine-sulfate/>, <https://onco.cc/technologies/nhs-targeted-lung-health-check/>, <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/technologies/robotic-bronchoscopy/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/oncomine-dx-target-test/>, <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/ventana-pd-l1-sp142/>, <https://onco.cc/drugs/caris-mi-cancer-seek/>, <https://onco.cc/drugs/resolution-ctdx-first/>, <https://onco.cc/drugs/necitumumab/>, <https://onco.cc/drugs/talc-sclerosant/>, <https://onco.cc/drugs/samarium-153-lexidronam/> ;
  onco:companies <https://onco.cc/companies/kanvas-biosciences/>, <https://onco.cc/companies/nanjing-leads-biolabs/>, <https://onco.cc/companies/avistone-biotechnology/>, <https://onco.cc/companies/catalym/>, <https://onco.cc/companies/shanghai-fosun-pharmaceutical-industrial-development/>, <https://onco.cc/companies/bioinvent-international/>, <https://onco.cc/companies/haihe-biopharma/>, <https://onco.cc/companies/multitude-therapeutics/>, <https://onco.cc/companies/orion-orion-pharma/>, <https://onco.cc/companies/epicentrx/>, <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/ap-biosciences/>, <https://onco.cc/companies/celltrion/>, <https://onco.cc/companies/civatech-oncology/>, <https://onco.cc/companies/elpiscience-suzhou-biopharma/>, <https://onco.cc/companies/genprex/>, <https://onco.cc/companies/ionctura/>, <https://onco.cc/companies/krystal-biotech/>, <https://onco.cc/companies/mabxience-research-s-l/>, <https://onco.cc/companies/maia-biotechnology/>, <https://onco.cc/companies/mbrace-therapeutics/>, <https://onco.cc/companies/molecular-partners/>, <https://onco.cc/companies/stcube/>, <https://onco.cc/companies/vyriad/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/boehringer-ingelheim/>, <https://onco.cc/companies/nuvalent/>, <https://onco.cc/companies/akeso/>, <https://onco.cc/companies/summit-therapeutics/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/nsclc-signalling/> ;
  onco:terms <https://onco.cc/terms/tps/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/egfr-exon20-insertion/>, <https://onco.cc/terms/c797s/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/oligoprogression/>, <https://onco.cc/terms/histology/> ;
  onco:trials <https://onco.cc/trials/gefitinib-chemo-tmh/>, <https://onco.cc/trials/symbiotic-lung-04/>, <https://onco.cc/trials/symbiotic-lung-01/>, <https://onco.cc/trials/nct06980272/>, <https://onco.cc/trials/nct06612151/>, <https://onco.cc/trials/nct07739758/>, <https://onco.cc/trials/nct06616532/>, <https://onco.cc/trials/nct07174908/>, <https://onco.cc/trials/nct07155187/>, <https://onco.cc/trials/nct07005102/>, <https://onco.cc/trials/nct05211895/>, <https://onco.cc/trials/nct05502237/>, <https://onco.cc/trials/nct05020769/>, <https://onco.cc/trials/nct05221840/>, <https://onco.cc/trials/nct06498479/>, <https://onco.cc/trials/nct07189455/>, <https://onco.cc/trials/nct07554339/>, <https://onco.cc/trials/nct06345729/>, <https://onco.cc/trials/nct07431827/>, <https://onco.cc/trials/nct07190248/>, <https://onco.cc/trials/nct06954246/>, <https://onco.cc/trials/nsclc-2/>, <https://onco.cc/trials/nct05450692/>, <https://onco.cc/trials/sqnsclc/>, <https://onco.cc/trials/nct07416994/>, <https://onco.cc/trials/nct05132075/>, <https://onco.cc/trials/nct05487391/>, <https://onco.cc/trials/nct05690945/>, <https://onco.cc/trials/nct07063745/>, <https://onco.cc/trials/nct06247605/>, <https://onco.cc/trials/nct07459751/>, <https://onco.cc/trials/nct06927986/>, <https://onco.cc/trials/nct07365319/>, <https://onco.cc/trials/nct07668752/>, <https://onco.cc/trials/nct05973773/>, <https://onco.cc/trials/nct07128199/>, <https://onco.cc/trials/aurora/>, <https://onco.cc/trials/nct06754644/>, <https://onco.cc/trials/nct05671510/>, <https://onco.cc/trials/dllevate/>, <https://onco.cc/trials/nct06671379/>, <https://onco.cc/trials/nct07365241/>, <https://onco.cc/trials/fleteo/>, <https://onco.cc/trials/nsclc-3/>, <https://onco.cc/trials/nct06984588/>, <https://onco.cc/trials/nct06416410/>, <https://onco.cc/trials/nct06735391/>, <https://onco.cc/trials/nct06635824/>, <https://onco.cc/trials/nct04655976/>, <https://onco.cc/trials/nct07566052/>, <https://onco.cc/trials/nct07662395/>, <https://onco.cc/trials/nct07217301/>, <https://onco.cc/trials/nct06646276/>, <https://onco.cc/trials/nct07362459/>, <https://onco.cc/trials/nct06472245/>, <https://onco.cc/trials/nsclc-4/>, <https://onco.cc/trials/nct06417008/>, <https://onco.cc/trials/nct06080776/>, <https://onco.cc/trials/nct06123754/>, <https://onco.cc/trials/luminosity/>, <https://onco.cc/trials/jcog0403/>, <https://onco.cc/trials/chisel/>, <https://onco.cc/trials/nct06712316/>, <https://onco.cc/trials/nct05687266/>, <https://onco.cc/trials/nct02486718/>, <https://onco.cc/trials/nct06119581/>, <https://onco.cc/trials/nct03164616/>, <https://onco.cc/trials/nct05555732/>, <https://onco.cc/trials/nct06627647/>, <https://onco.cc/trials/nct06692738/>, <https://onco.cc/trials/nct02453282/>, <https://onco.cc/trials/nct03178552/>, <https://onco.cc/trials/nct06561386/>, <https://onco.cc/trials/nct02542293/>, <https://onco.cc/trials/nct05984277/>, <https://onco.cc/trials/nct07513376/>, <https://onco.cc/trials/nct04380636/>, <https://onco.cc/trials/nct06077760/>, <https://onco.cc/trials/nct06422143/>, <https://onco.cc/trials/nct07361497/>, <https://onco.cc/trials/nct06868277/>, <https://onco.cc/trials/nct03800134/>, <https://onco.cc/trials/nct06312137/>, <https://onco.cc/trials/nct06767514/>, <https://onco.cc/trials/nct04988295/>, <https://onco.cc/trials/nct06012435/>, <https://onco.cc/trials/nct06726265/>, <https://onco.cc/trials/nct05920356/>, <https://onco.cc/trials/nct07361510/>, <https://onco.cc/trials/nct06417814/>, <https://onco.cc/trials/nct05215340/>, <https://onco.cc/trials/nct06216301/>, <https://onco.cc/trials/nct06687369/>, <https://onco.cc/trials/nct03833154/>, <https://onco.cc/trials/nct06838273/>, <https://onco.cc/trials/nct06758401/>, <https://onco.cc/trials/nct06890598/>, <https://onco.cc/trials/nct06382129/>, <https://onco.cc/trials/nct06899126/>, <https://onco.cc/trials/nct06623422/>, <https://onco.cc/trials/nct06357533/>, <https://onco.cc/trials/nct03003962/>, <https://onco.cc/trials/nct03390686/>, <https://onco.cc/trials/nct06875310/>, <https://onco.cc/trials/nct04613596/>, <https://onco.cc/trials/nct04923906/>, <https://onco.cc/trials/nct05654454/>, <https://onco.cc/trials/nct05609968/>, <https://onco.cc/trials/nct06170788/>, <https://onco.cc/trials/nct05089734/>, <https://onco.cc/trials/nct05987956/>, <https://onco.cc/trials/nct06793215/>, <https://onco.cc/trials/nct06881784/>, <https://onco.cc/trials/nct06350097/>, <https://onco.cc/trials/nct07183189/>, <https://onco.cc/trials/nct06041776/>, <https://onco.cc/trials/nct06617416/> ;
  onco:journals <https://onco.cc/journals/clinical-lung-cancer/>, <https://onco.cc/journals/lung-cancer-journal/>, <https://onco.cc/journals/thoracic-cancer/>, <https://onco.cc/journals/chinese-journal-of-lung-cancer/> ;
  onco:pipeline <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/tilatamig-samrotecan/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/drugs/zidesamtinib/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/shr-8068/>, <https://onco.cc/drugs/yl201/>, <https://onco.cc/drugs/shr-a2102/>, <https://onco.cc/drugs/tqb2102/>, <https://onco.cc/drugs/pm8002/>, <https://onco.cc/drugs/in10018/>, <https://onco.cc/drugs/telisotuzumab-adizutecan/>, <https://onco.cc/drugs/domvanalimab/>, <https://onco.cc/drugs/si-b001/>, <https://onco.cc/drugs/oleclumab/>, <https://onco.cc/drugs/cetrelimab/>, <https://onco.cc/drugs/hs-20093/>, <https://onco.cc/drugs/zg006/>, <https://onco.cc/drugs/calderasib/>, <https://onco.cc/drugs/ak117/>, <https://onco.cc/drugs/qlc5508/>, <https://onco.cc/drugs/budigalimab/>, <https://onco.cc/drugs/ceralasertib/>, <https://onco.cc/drugs/rc148/>, <https://onco.cc/drugs/yl202/>, <https://onco.cc/drugs/livmoniplimab/>, <https://onco.cc/drugs/jdq443/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/ql1706/>, <https://onco.cc/drugs/monalizumab/>, <https://onco.cc/drugs/navlimetostat/>, <https://onco.cc/drugs/al8326/>, <https://onco.cc/drugs/hlx43/>, <https://onco.cc/drugs/sys6010/>, <https://onco.cc/drugs/kl-a167/>, <https://onco.cc/drugs/quemliclustat/>, <https://onco.cc/drugs/eik1001/>, <https://onco.cc/drugs/gfh375/>, <https://onco.cc/drugs/zipalertinib/>, <https://onco.cc/drugs/aglatimagene-besadenovec/>, <https://onco.cc/drugs/ql2107/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/tqb2450/>, <https://onco.cc/drugs/zl-1310/>, <https://onco.cc/drugs/shr-a2009/>, <https://onco.cc/drugs/pf-07248144/>, <https://onco.cc/drugs/abbv-706/>, <https://onco.cc/drugs/ty-9591/>, <https://onco.cc/drugs/tgrx-326/>, <https://onco.cc/drugs/uliledlimab/>, <https://onco.cc/drugs/sitneprotafib/>, <https://onco.cc/drugs/jmt101/>, <https://onco.cc/drugs/acasunlimab/>, <https://onco.cc/drugs/bnt324/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/drugs/olvimulogene-nanivacirepvec/>, <https://onco.cc/drugs/setidegrasib/>, <https://onco.cc/drugs/sctb41/>, <https://onco.cc/drugs/tak-928/>, <https://onco.cc/drugs/atigotatug/>, <https://onco.cc/drugs/sctb14/>, <https://onco.cc/drugs/ose2101/>, <https://onco.cc/drugs/pf-08046054/>, <https://onco.cc/drugs/hs-20117/>, <https://onco.cc/drugs/ibi363/>, <https://onco.cc/drugs/vs-7375/>, <https://onco.cc/drugs/t3011/>, <https://onco.cc/drugs/tng462/>, <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/tqb6411/>, <https://onco.cc/drugs/anvumetostat/>, <https://onco.cc/drugs/xnw27011/>, <https://onco.cc/drugs/hmbd-001/>, <https://onco.cc/drugs/ssgj-706/>, <https://onco.cc/drugs/ep0031/>, <https://onco.cc/drugs/absk061/>, <https://onco.cc/drugs/rilvegostomig/>, <https://onco.cc/drugs/mavrostobart/>, <https://onco.cc/drugs/hb0036/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/tri-611/>, <https://onco.cc/drugs/silevertinib/>, <https://onco.cc/drugs/palacaparib/>, <https://onco.cc/drugs/peluntamig/>, <https://onco.cc/drugs/tng456/>, <https://onco.cc/drugs/jyp0015/>, <https://onco.cc/drugs/hlx26/>, <https://onco.cc/drugs/ba3071/>, <https://onco.cc/drugs/env-501/>, <https://onco.cc/drugs/azd7789/>, <https://onco.cc/drugs/vrn110755/>, <https://onco.cc/drugs/dji136/>, <https://onco.cc/drugs/js111/>, <https://onco.cc/drugs/tng260/>, <https://onco.cc/drugs/au-007/>, <https://onco.cc/drugs/or502/>, <https://onco.cc/drugs/jmt203/>, <https://onco.cc/drugs/befotertinib/>, <https://onco.cc/drugs/lp-184/>, <https://onco.cc/drugs/upifitamab-rilsodotin/>, <https://onco.cc/drugs/vibostolimab/>, <https://onco.cc/drugs/boserolimab/>, <https://onco.cc/drugs/neladalkib/>, <https://onco.cc/trials/alkove-1/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/trials/krascendo-1/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/trials/harmoni-3/>, <https://onco.cc/trials/telimet-nsclc-01/>, <https://onco.cc/drugs/sevabertinib/>, <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/radiology-ai-screening/>, <https://onco.cc/technologies/immuno-pet/> ;
  onco:standardOfCare <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/radiology-ai-screening/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/technologies/low-dose-ct-screening/>, <https://onco.cc/trials/nlst-nelson/>, <https://onco.cc/technologies/robotic-bronchoscopy/>, <https://onco.cc/technologies/radiology-ai-screening/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/trials/checkmate-816/>, <https://onco.cc/trials/keynote-671/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/alina/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/pacific/>, <https://onco.cc/trials/laura/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/trials/flaura2/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/trials/mariposa/>, <https://onco.cc/pairings/amivantamab-plus-lazertinib/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/trials/tropion-lung05/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/c797s/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/terms/egfr-exon20-insertion/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/trials/crown/>, <https://onco.cc/drugs/alectinib/>, <https://onco.cc/drugs/neladalkib/>, <https://onco.cc/trials/alkove-1/>, <https://onco.cc/terms/oligoprogression/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/zidesamtinib/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/trials/codebreak-200/>, <https://onco.cc/trials/krystal-12/>, <https://onco.cc/trials/krascendo-1/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/targets/braf/>, <https://onco.cc/drugs/capmatinib-tepotinib/>, <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/trials/telimet-nsclc-01/>, <https://onco.cc/targets/met/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/trials/libretto-431/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/targets/ret/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/sevabertinib/>, <https://onco.cc/trials/soho-01/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/targets/her2/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/trials/harmoni-2/>, <https://onco.cc/terms/tps/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/pairings/pd1-plus-chemo-pdl1-low/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/trials/harmoni-3/> .